Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
$19.31M+13.6%$16.99M-3.6%$17.63M-1.3%$17.86M+4.7%$17.05M+28.0%
$5.12M+3.6%$4.94M-6.2%$5.26M+6.4%$4.95M-3.3%$5.12M+3.4%
$24.43M+11.4%$21.93M-4.2%$22.9M+0.4%$22.81M+2.9%$22.17M+21.4%
-$24.43M-11.4%-$21.93M+4.2%-$22.9M-0.4%-$22.81M-2.9%-$22.17M-21.4%
$914K-21.2%$1.16M-15.3%$1.37M-12.0%$1.56M-16.3%$1.86M-14.4%
-$23.52M-13.2%-$20.77M+3.5%-$21.53M-1.3%-$21.25M-4.6%-$20.31M-26.2%
-$0.95-13.1%-$0.84+4.5%-$0.88-1.1%-$0.87-4.8%-$0.83
-$23.76M-11.7%-$21.27M+4.4%-$22.24M-0.3%-$22.17M-2.9%-$21.54M-22.0%
-$24.43M-11.4%-$21.93M+4.2%-$22.9M-0.4%-$22.81M-2.9%-$22.17M-21.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Artiva Biotherapeutics, Inc. profitable?
Artiva Biotherapeutics, Inc. is not currently profitable: it reported a net loss of $87.1M over the trailing twelve months, a -79.3% net margin.
What is Artiva Biotherapeutics, Inc.'s earnings per share?
Artiva Biotherapeutics, Inc.'s diluted EPS over the trailing twelve months is $-3.54.
Where does Artiva Biotherapeutics, Inc.'s income statement data come from?
Every line is extracted from Artiva Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.